Xuejiao Fan, Na Li. Letter: Optimising Patient Selection for TACE Plus Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma. // Alimentary Pharmacology and Therapeutics. – 2026. – DOI: 10.1111/apt.70801. – URL: https://onlinelibrary.wiley.com/doi/10.1111/apt.70801?af=R
Xuejiao Fan & Na Li (2026). Letter: Optimising Patient Selection for TACE Plus Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma. Alimentary Pharmacology and Therapeutics. https://doi.org/10.1111/apt.70801
Xuejiao Fan and Na Li. “Letter: Optimising Patient Selection for TACE Plus Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma.” Alimentary Pharmacology and Therapeutics, 2026. doi:10.1111/apt.70801.
@article{Fan2026,
title = {Letter: Optimising Patient Selection for TACE Plus Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma},
author = {Fan, Xuejiao and Li, Na},
journal = {Alimentary Pharmacology and Therapeutics},
year = {2026},
doi = {10.1111/apt.70801},
url = {https://onlinelibrary.wiley.com/doi/10.1111/apt.70801?af=R}
}